No Data
Xintian Pharmaceutical: Report for the third quarter of 2024
Guiyang Xintian Pharmaceutical (002873.SZ) released its performance for the first three quarters, with a net income of 60.9998 million yuan, a year-on-year decrease of 30.45%.
Guiyang Xintian Pharmaceutical (002873.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
The concept of innovative drugs in A-shares is active, with Guiyang Xintian Pharmaceutical and Jiangsu Sihuan Bioengineering hitting the daily limit.
Gelonghui October 24th | Guiyang Xintian Pharmaceutical, Jiangsu Sihuan Bioengineering limit up, Hainan Poly Pharm, Beijing Beilu Pharmaceutical, Huosen Biology and other leading gains.
Guiyang Xintian Pharma Gets Nod for Addition of Chinese Herbal Medicine Pieces to Production License
Guiyang Xintian Pharmaceutical Unit Changes Name
Xintian Pharmaceutical: 2024 Semi-Annual Report Summary
No Data
No Data